News
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 (see chart 2). Lilly’s edge rests on a more effective drug, better execution, keener pricing and a stronger pipeline.
According to a study funded by Eli Lilly, the trial revealed that participants taking tirzepatide, the drug sold as ...
Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...
The best metric is not weight, but a particularly toxic kind of fat.
A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback